We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Who’s on the FDA’s Advisory Panel That Will Review Pfizer’s Vaccine?

Who’s on the FDA’s Advisory Panel That Will Review Pfizer’s Vaccine?

December 7, 2020

The FDA has had trouble finding members for its vaccine advisory committee that will meet on Dec. 10, to consider recommending Emergency Use Authorization (EUA) for Pfizer’s COVID-19 vaccine candidate — surely one of the most important advisory panel meetings in the agency’s history.

FDA advisory committee members in the past have frequently been the target of heavy politicking by industry representatives of whatever drug they were considering for a recommendation at in-person meetings. That process has been somewhat altered by the fact that during COVID-19, meetings are being held virtually. But it’s likely that behind-the-scenes pressuring still goes on. The industry defends the attempts to influence committee members as simply efforts to best present their case.

One temporary voting member was just added to the panel on Nov. 24 — James Hildreth, president and chief executive officer of Meharry Medical College in Nashville, Tenn. Meharry is an approved site for a trial of Novavax’s COVID-19 vaccine candidate, NVX-CoV2373, being conducted by the NIH as part of Operation Warp Speed. While acknowledging a potential financial conflict of interest, as the college will receive between $500,000 and $750,000 for the Novavax trial, the waiver document asserts that Hildreth’s “strong and significant scientific background in virology and immunology will be critical” to the advisory group’s recommendation.

“It would be impossible to replace Dr. Hildreth (especially in view of previous multiple recusals of invited participants) and excluding him from participation will have a negative effect on the committee deliberations,” said Atreya Prabhakara, the FDA’s director for scientific advisers and consultants within the Center for Biologics, Evaluation and Research.

But who else is on the 15-member advisory committee that usually works far away from the media’s intense scrutiny? It is made up mostly of experts from the academic community, and the current line-up of doctors and researchers from universities, cancer centers and teaching hospitals includes:

  • The committee’s chairperson Hana El Sahly, from Baylor College of Medicine in Houston, Texas;
  • Archana Chatterjee, from Rosalind Franklin University of Medicine and Science in North Chicago, Ill;
  • Hayley Gans, from Stanford University in Stanford, Conn.;
  • Holly Janes, Fred Hutchinson Cancer Research Center in Seattle, Wash.;
  • Myron Levine, from the University of Maryland in Baltimore, Md.;
  • H. Cody Meissner, from Tufts University in Boston, Mass.;
  • Paul Offit, from the Children’s Hospital of Philadelphia, Penn.;
  • Steven Pergam, from the Seattle Cancer Care Alliance, Wash.;
  • Andrea Shane, from Emory University in Atlanta, Ga.;
  • Paul Spearman, from Cincinnati Children’s Hospital, Ohio.; and
  • Geeta Swamy, from Duke University in Durham, N.C.

The HHS representatives, which includes personnel from the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) are:

  • Tammy Beckham, HHS, vaccines and infectious diseases director;
  • Capt. Amanda Cohn, acting chief medical officer for vaccines at the CDC; and
  • Michael Kurilla, director of clinical innovation for advancing translational sciences at NIH.

Paula Annunziato, Merck’s vice president and therapeutic area head for vaccines clinical research, is the non-voting member from industry, but the committee also includes an alternate industry representative, Gregg Sylvester, vice president of medical affairs at N.J.-based Seqirus, a subsidiary of Australian biotech firm CSL.

Representing consumer groups is another non-voting member, health benefits lawyer Sheldon Toubman, a staff attorney at the New Haven Legal Assistance Association in Connecticut.

Each member is chosen by FDA Commissioner Stephen Hahn or a “designee” through a nomination process, with experts solicited via notices published in the Federal Register. Members serve for overlapping terms of no more than four years and are pulled from the fields of: “immunology, molecular biology, rDNA, virology, bacteriology, epidemiology or biostatistics, vaccine policy, vaccine safety science, federal immunization activities, vaccine development, allergy, preventive medicine, infectious diseases, pediatrics, microbiology and biochemistry.” ― Jason Scott

COVID-19

Upcoming Events

  • 01Feb

    The Future of QMS: Will the Recent Announcement and Delays Have a Global Impact?

  • 08Feb

    Process and Design Validation for Devicemakers: A Deep Dive into Best Practices, Recent Trends and Regulatory Definitions

  • 09Feb

    The Inextricable Link Between Data Integrity and Quality Culture

  • 15Feb

    Advanced Compliance Writing CAPA: Mastering Failure Investigation and Root Cause Analysis

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 22Feb

    Best Practices for Developing and Maintaining a GxP Training Matrix

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • NeuroMetrix Launches DPNCheck 2.0 for Peripheral Neuropathy Screening

  • Syros Gets Fast Track Status for Higher-Risk Myelodysplastic Syndrome Candidate

  • FDA Approves Abbott’s Spinal Cord Stimulation System for Diabetic Peripheral Neuropathy

  • FDA Expands Approval for Merck’s Keytruda in NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing